

Yi Hu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3775725/yi-hu-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33
papers

36,111
citations

18
h-index

41
g-index

41
ext. papers

46,189
ext. citations

10
avg, IF

7.6
L-index

#	Paper	IF	Citations
33	Total infectome characterization of respiratory infections in pre-COVID-19 Wuhan, China.. <i>PLoS Pathogens</i> , 2022 , 18, e1010259	7.6	2
32	The application of transbronchial cryobiopsy in interstitial lung disease: a prospective, multicenter, real-world study.. <i>Annals of Translational Medicine</i> , 2021 , 9, 1645	3.2	
31	Rs2686344 and serum squamous cell carcinoma antigen could predict clinical efficacy of neoadjuvant chemotherapy for cervical cancer. <i>Current Problems in Cancer</i> , 2021 , 45, 100755	2.3	0
30	Comparison of Immediate and Sequential Withdrawal of a Systemic Glucocorticoid in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Parallel-Controlled, Open-Label Study. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 639079	5.6	
29	3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 747-754	35.1	127
28	Efficacy of rapid on-site cytological evaluation (ROSE) by a pulmonologist in determining specimen adequacy and diagnostic accuracy in interventional diagnosis of lung lesions. <i>Journal of International Medical Research</i> , 2021 , 49, 300060520982687	1.4	1
27	Identification of a Six-Gene SLC Family Signature With Prognostic Value in Patients With Lung Adenocarcinoma.. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 803198	5.7	1
26	Non-invasive respiratory support for patients with novel coronavirus pneumonia: clinical efficacy and reduction in risk of infection transmission. <i>Chinese Medical Journal</i> , 2020 , 133, 1109-1111	2.9	9
25	Predictive factors of severe coronavirus disease 2019 in previously healthy young adults: a single-center, retrospective study. <i>Respiratory Research</i> , 2020 , 21, 157	7.3	24
24	Development of an automatic integrated gene detection system for novel severe acute respiratory syndrome-related coronavirus (SARS-CoV2). <i>Emerging Microbes and Infections</i> , 2020 , 9, 1489-1496	18.9	15
23	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. <i>Chinese Medical Journal</i> , 2020 , 133, 1032-1038	2.9	580
22	Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. <i>PLoS ONE</i> , 2020 , 15, e0230548	3.7	305
21	Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. <i>Chinese Medical Journal</i> , 2020 , 133, 1015-1024	2.9	619
20	A new coronavirus associated with human respiratory disease in China. <i>Nature</i> , 2020 , 579, 265-269	50.4	6055
19	Effect of hypertension on outcomes of adult inpatients with COVID-19 in Wuhan, China: a propensity score-matching analysis. <i>Respiratory Research</i> , 2020 , 21, 172	7.3	21
18	Temporal radiographic changes in COVID-19 patients: relationship to disease severity and viral clearance. <i>Scientific Reports</i> , 2020 , 10, 10263	4.9	12
17	Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. <i>Lancet, The</i> , 2020 , 395, 497-506	40	25240

16	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2020 , 395, 1569-1578	40	2070
15	Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. <i>Trials</i> , 2020 , 21, 422	2.8	43
14	On the use of corticosteroids for 2019-nCoV pneumonia. <i>Lancet, The</i> , 2020 , 395, 683-684	40	399
13	Different Laboratory Abnormalities in COVID-19 Patients with Hypertension or Diabetes. <i>Virologica Sinica</i> , 2020 , 35, 853-856	6.4	0
12	High-Flow Nasal Oxygen in Coronavirus Disease 2019 Patients With Acute Hypoxemic Respiratory Failure: A Multicenter, Retrospective Cohort Study. <i>Critical Care Medicine</i> , 2020 , 48, e1079-e1086	1.4	31
11	Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in Wuhan, China. <i>Respiration</i> , 2020 , 99, 649-657	3.7	21
10	Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. <i>Journal of Infection</i> , 2020 , 81, e95-e97	18.9	98
9	Hospitalization and Critical Care of 109 Decedents with COVID-19 Pneumonia in Wuhan, China. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 839-846	4.7	138
8	Obesity predisposes to the risk of higher mortality in young COVID-19 patients. <i>Journal of Medical Virology</i> , 2020 , 92, 2536-2542	19.7	63
7	Expression profile and prognostic value of SFN in human ovarian cancer. <i>Bioscience Reports</i> , 2019 , 39,	4.1	6
6	Integrin- α expression positively correlates with CD44 and CD133 expressions, and its high expression associates with advanced tumor features as well as poor survivals in non-small cell lung cancer patients.. <i>Translational Cancer Research</i> , 2019 , 8, 1806-1816	0.3	
5	Atorvastatin Attenuates Myocardial Hypertrophy Induced by Chronic Intermittent Hypoxia In Vitro Partly through miR-31/PKCIPathway. <i>Current Medical Science</i> , 2018 , 38, 405-412	2.8	13
4	miR-486-5p inhibits cell proliferation and invasion through repressing GAB2 in non-small cell lung cancer. <i>Oncology Letters</i> , 2018 , 16, 3525-3530	2.6	16
3	Current treatment of tracheoesophageal fistula. <i>Therapeutic Advances in Respiratory Disease</i> , 2017 , 11, 173-180	4.9	26
2	Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines. <i>Oncology Letters</i> , 2017 , 13, 4619-4626	2.6	6
1	IGFBP-4 expression is adversely associated with lung cancer prognosis. <i>Oncology Letters</i> , 2017 , 14, 6876-6880	8	8